CVALF
Price
$1.66
Change
-$0.04 (-2.35%)
Updated
Sep 4 closing price
Capitalization
45.32M
SMMT
Price
$25.98
Change
+$2.18 (+9.16%)
Updated
Sep 5 closing price
Capitalization
19.3B
59 days until earnings call
Interact to see
Advertisement

CVALF vs SMMT

Header iconCVALF vs SMMT Comparison
Open Charts CVALF vs SMMTBanner chart's image
Covalon Technologies
Price$1.66
Change-$0.04 (-2.35%)
Volume$201
Capitalization45.32M
Summit Therapeutics
Price$25.98
Change+$2.18 (+9.16%)
Volume$3.41M
Capitalization19.3B
CVALF vs SMMT Comparison Chart in %
Loading...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVALF vs. SMMT commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Hold and SMMT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (CVALF: $1.66 vs. SMMT: $25.98)
Brand notoriety: CVALF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 2% vs. SMMT: 106%
Market capitalization -- CVALF: $45.32M vs. SMMT: $19.3B
CVALF [@Biotechnology] is valued at $45.32M. SMMT’s [@Biotechnology] market capitalization is $19.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 2 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • CVALF’s TA Score: 2 bullish, 8 bearish.
  • SMMT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than CVALF.

Price Growth

CVALF (@Biotechnology) experienced а -3.49% price change this week, while SMMT (@Biotechnology) price change was +9.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($19.3B) has a higher market cap than CVALF($45.3M). SMMT (26.36) and CVALF (25.44) have similar P/E ratio . SMMT YTD gains are higher at: 45.587 vs. CVALF (-25.893). CVALF has higher annual earnings (EBITDA): 4.73M vs. SMMT (-743.48M). SMMT has more cash in the bank: 298M vs. CVALF (18M). CVALF has less debt than SMMT: CVALF (609K) vs SMMT (5.55M). CVALF has higher revenues than SMMT: CVALF (33.8M) vs SMMT (0).
CVALFSMMTCVALF / SMMT
Capitalization45.3M19.3B0%
EBITDA4.73M-743.48M-1%
Gain YTD-25.89345.587-57%
P/E Ratio25.4426.3697%
Revenue33.8M0-
Total Cash18M298M6%
Total Debt609K5.55M11%
FUNDAMENTALS RATINGS
CVALF vs SMMT: Fundamental Ratings
CVALF
SMMT
OUTLOOK RATING
1..100
5081
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
6139
SMR RATING
1..100
54100
PRICE GROWTH RATING
1..100
7840
P/E GROWTH RATING
1..100
699
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (63) in the null industry is in the same range as SMMT (95) in the Biotechnology industry. This means that CVALF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (39) in the Biotechnology industry is in the same range as CVALF (61) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

CVALF's SMR Rating (54) in the null industry is somewhat better than the same rating for SMMT (100) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for CVALF (78) in the null industry. This means that SMMT’s stock grew somewhat faster than CVALF’s over the last 12 months.

SMMT's P/E Growth Rating (9) in the Biotechnology industry is somewhat better than the same rating for CVALF (69) in the null industry. This means that SMMT’s stock grew somewhat faster than CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFSMMT
RSI
ODDS (%)
Bearish Trend 3 days ago
67%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
61%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
64%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NBH10.090.24
+2.44%
Neuberger Berman Municipal Fund
EUDG35.170.13
+0.36%
WisdomTree Europe Quality Div Gr ETF
FPEI19.210.02
+0.10%
First Trust Instl Pref Secs and Inc ETF
TGONF17.80N/A
N/A
Tetragon Financial Group
EFZ13.61-0.08
-0.60%
ProShares Short MSCI EAFE

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
N/A
SMMT - CVALF
27%
Poorly correlated
+9.16%
GNFT - CVALF
25%
Poorly correlated
+1.53%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
-0.63%
MBIO - CVALF
20%
Poorly correlated
-2.72%
More